Reliance Global Group Advances Digital Brokerage and AI Diagnostics Amid Profitability Headwinds
The company reported strong policy growth on its RELI Exchange platform alongside continued operating losses and strategic AI sector investments.
Reliance Global Group, Inc. (EZRA) achieved significant expansion in health insurance policies and personal lines premiums through its RELI Exchange InsurTech platform in 2025. Despite this volume growth, the company faced an 11.6% revenue decline and increased operating losses. The strategic acquisition of a milestone-based majority stake in AI breath diagnostics firm Enquantum Ltd. highlights diversification efforts, balanced by execution risks tied to milestone achievement. Operating cash flow remained negative, with no dividends or buybacks declared, indicating a focus on reinvestment during ongoing profitability challenges.
Robust Policy Growth during Revenue Contraction
Historical performance (annual)
| FY | Rev ($mm) | Net ($mm) | CFO ($mm) | OpInc ($mm) | Rev YoY | Net YoY |
|---|---|---|---|---|---|---|
| 2025 | 12 | -7 | -3 | -9 | -11.6% | +23.0% |
| 2024 | 14 | -9 | -3 | -8 | +2.3% | +24.5% |
| 2023 | 14 | -12 | -1 | -14 | -18.0% | -285.7% |
| 2022 | 17 | 6 | -3 | -22 |
Source: SEC companyfacts cache [F1].
Capital returns and efficiency (annual)
| FY | FCF ($mm) | ROE% |
|---|---|---|
| 2025 | -3 | -108.7 |
| 2024 | -3 | -302.7 |
| 2023 | -1 | -168.0 |
| 2022 | -3 | 72.6 |
Source: SEC companyfacts cache [F1].
In 2025, Reliance Global Group's digital brokerage platform, RELI Exchange, delivered substantial volume growth, with health insurance policies increasing by 72% and personal lines property and casualty premiums rising approximately 36% year-over-year [N1][F1]. This reflects successful customer acquisition and distribution capabilities within their scalable InsurTech model.
Despite these gains, total revenues contracted by 11.6% to approximately $12.4 million compared to $14.05 million in FY2024 [F1]. The divergence between higher policy counts and lower revenue suggests shifts in product mix or pricing pressures impacting average premium per policy.
Such dynamics are common in early-stage InsurTech businesses where scale economies have yet to fully materialize.
Strategic Investment in AI Diagnostics Company
In early 2026, Reliance initiated a milestone-based investment to acquire up to a 51% controlling interest in Enquantum Ltd., an Israeli AI breath diagnostics firm [S8][N1]. The initial closing included conversion of a secured convertible promissory note valued at $166,000 into equity (approximately 4%) alongside an additional cash investment representing another approximate 4%, resulting in an aggregate ~8% ownership post-closing [S8][S26].
Total consideration could reach about $2.125 million disbursed upon meeting specified commercialization and operational milestones over roughly ten months [S8][S26]. The agreement grants Reliance first-ranking security interests over Enquantum’s assets including intellectual property [S6], mitigating investment risk.
Board representation was secured for CEO Ezra Beyman starting February 2026 as part of governance provisions [S26]. This strategic move diversifies Reliance’s business into healthcare AI diagnostics alongside its core insurance brokerage operations.
Financial Results Highlight Profitability Challenges
Reliance’s FY2025 results reveal continued profitability headwinds despite operational traction. Revenue declined by approximately $1.7 million (-11.6%) year-over-year to $12.4 million [F1]. Operating loss expanded by about $1.3 million (-17%), reaching nearly -$9 million [F1].
However, net loss narrowed by roughly $2.1 million (~23%) to just under -$7 million in FY2025 [F1], indicating some improvement in expense management or reduced non-operating costs.
Operating cash flow remained negative at approximately -$3.1 million for the year (worsening by ~23%) [F1], with modest capital expenditures near $16,000 reflecting conservative spending focused on maintenance rather than expansion [F1].
These results typify growth-stage InsurTech firms investing heavily ahead of achieving scale-driven profitability.
Capital Structure and Liquidity Positioning
Liquidity remains solid entering 2026 with current assets exceeding liabilities at a ratio near 1.78 as of December 31, 2025 [F1]. Recent capital raises totaled around $2 million net proceeds intended for working capital and strategic acquisitions such as the Enquantum transaction [S13][S21].
The company has also reduced contingent liabilities through settlements related to legacy stock purchase litigation involving CEO affiliates, approved unanimously by independent directors [S4][S5][S19], enhancing balance sheet stability.
No dividends or share repurchase programs have been declared through early-2026 filings [S14][S22][S26][S28], reflecting a focus on liquidity preservation amid ongoing investments.
Outlook and Risks
Reliance’s future growth depends on sustaining adoption momentum for the RELI Exchange platform to convert volume gains into revenue expansion amid pricing challenges [N1]. Achievement of Enquantum’s milestone targets is critical for securing majority ownership; delays or regulatory obstacles could impact anticipated synergies [S8].[N1]
Regulatory complexities arise from combining insurance brokerage services with healthcare AI diagnostics ventures requiring careful compliance management.
Negative operating cash flows highlight ongoing funding needs until profitable scale is reached.
Governance Enhancements via Settlements
Recent settlements resolving claims tied to stock purchase guarantees have eliminated contingent liabilities through modest cash payments ($40k and $90k), strengthening governance oversight and investor confidence during strategic transitions [S4][S5][S19].
Disclaimer: Analysis based solely on information available as of March 29, 2026, including SEC filings and publicly reported news items referenced herein, without investment advice or recommendations.
Disclaimer: This is research-only, informational analysis and not investment advice. It may include AI-generated interpretation and general industry context. Always verify important details using primary sources.
Comments